ARMP

Armata Pharmaceuticals, Inc. · AMEX

Sector Health Technology
Industry Biotechnology
Website armatapharma.com
Employees(FY) 72
ISIN US04216R1023

Performance

-7.14%

-1.52%

-12.56%

-29.6%

-39.81%

YTD

-20.08%

Profile

Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California.

Advanced Technical Analysis

Technical Analysis of ARMP 2024-12-20

The stock indicators reflect a bearish sentiment overall, with a Moving Average Score of 10 indicating strong downward momentum, an Oscillators Score of 43 suggesting a neutral stance, and a Technical Score of 26 reinforcing the bearish outlook. This combination points to a challenging environment for the stock, with potential weakness in price ...

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of ARMP

Stock Rank

Recent News & Updates

2024-12-19 18:15
Armata Pharmas inhaled AP-PA02 shows positive results in Phase 2 study(Yahoo Finance)
2024-12-18 18:00
Armata Pharmaceuticals Announces Encouraging Results from the Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection(Prnewswire)
2024-11-18 18:00
Armata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 5th Annual Phage Futures Annual Meeting(Prnewswire)
2024-11-13 03:05
Armata Pharmaceuticals Announces Third Quarter 2024 Results and Provides Corporate Update(Prnewswire)
2024-11-11 18:00
Armata Pharmaceuticals Announces the Completion of Enrollment of its Phase 1b/2a diSArm Study Evaluating Intravenous AP-SA02 as a Potential Treatment for Staphylococcus aureus Bacteremia(Prnewswire)
2024-10-29 19:00
Armata Pharmaceuticals Announces Structural Biology Publication(Prnewswire)
2024-09-12 00:00
Armata Pharmaceuticals (ARMP) Upgraded to Buy: What Does It Mean for the Stock?(Yahoo Finance)
2024-09-04 19:30
Armata Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference(Prnewswire)
2024-08-25 19:30
Armata Pharmaceuticals Announces Presentation at the 2024 Military Health System Research Symposium(Prnewswire)
2024-08-15 04:45
Armata Pharmaceuticals Announces Appointment of Life Sciences Accounting and Finance Veteran David House as SVP of Finance and Principal Financial Officer(Prnewswire)
2024-08-13 04:05
Armata Pharmaceuticals Announces Second Quarter 2024 Results and Provides Corporate Update(Prnewswire)
2024-07-29 19:00
Armata Pharmaceuticals Receives $5.25 Million of Additional Non-Dilutive Grant Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02(Prnewswire)
2024-07-10 19:00
Armata Pharmaceuticals Announces Completion of Enrollment of Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection(Prnewswire)
2024-07-10 04:05
Armata Pharmaceuticals Announces Presentation at Viruses of Microbes 2024(Prnewswire)
2024-05-07 04:01
Armata Pharmaceuticals Announces First Quarter 2024 Results and Provides Corporate Update(Prnewswire)
2024-03-21 04:05
Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2023 Results and Provides Corporate Update(Prnewswire)
2024-03-04 03:01
Armata Pharmaceuticals Announces $35 Million Secured Credit Agreement with Innoviva(Yahoo Finance)
2024-02-20 18:00
Armata Pharmaceuticals Announces Presentation at the 6th Annual Bacteriophage Therapy Summit(Yahoo Finance)
2023-11-14 03:00
Armata Pharmaceuticals Announces Third Quarter 2023 Results and Provides Corporate Update(Yahoo Finance)
2023-10-29 20:00
Armata Pharmaceuticals Announces Presentation of Topline Data from SWARM-P.a. Clinical Study at the North American Cystic Fibrosis Conference(Yahoo Finance)
2023-10-18 20:00
Armata Pharmaceuticals Announces Presentation at Phage Futures: Global Digital Summit 2023(Yahoo Finance)
2023-09-25 20:00
Armata Pharmaceuticals Announces First Patient Dosed in the Phase 2a Portion of the Phase 1b/2a 'diSArm' Study of AP-SA02 in Adults with Bacteremia Due to Staphylococcus aureus(Yahoo Finance)
2023-09-20 19:00
Armata Pharmaceuticals to Participate in the Cantor Global Healthcare Conference(Yahoo Finance)
2023-08-16 21:55
Armata Pharmaceuticals, Inc. (ARMP) Now Trades Above Golden Cross: Time to Buy?(Yahoo Finance)
2023-08-13 19:00
Armata Pharmaceuticals Announces Second Quarter 2023 Results and Provides Corporate Update(Yahoo Finance)
2023-07-10 20:00
Armata Pharmaceuticals Announces New Financing and Leadership Transition to Accelerate Novel Bacteriophage Therapeutics(Yahoo Finance)
2023-05-30 20:00
Armata Pharmaceuticals Announces Oral Presentation Detailing Results from the Phase 1b/2a SWARM-P.a. Clinical Trial at the 6th World Conference on Targeting Phage Therapy(Yahoo Finance)
2023-05-11 04:05
Armata Pharmaceuticals Announces First Quarter 2023 Results and Provides Corporate Update(Yahoo Finance)
2023-03-16 04:10
Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2022 Results and Provides Corporate Update(Yahoo Finance)
2023-03-05 17:00
Armata Pharmaceuticals Announces Positive Topline Data from Phase 1b/2a SWARM-P.a. Clinical Trial of Inhaled AP-PA02 in Patients with Cystic Fibrosis(Yahoo Finance)

Page 1 of 4

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.